Results 11 to 20 of about 212,261 (297)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism [PDF]

Endocrine Connections, 2018
Background: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy.
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe   +3 more
doaj   +5 more sources

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis

Chinese Medical Journal, 2017
Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism.
Qiang Liu, Chun-Sheng Li
doaj   +3 more sources

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo

Journal of the Egyptian Women’s Dermatologic Society
Background Programmed cell death 1 (PD-1) is a cell surface protein that serves as an immune checkpoint in conjunction with its two ligands, PD-L1 and PD-L2.
Hanan R. Nada, Ahmed Mourad, Laila A. Rashed, Ghada M. El-Hanafy, Nermeen M.A. Abdallah, Mohamed M. Abdelhady   +5 more
doaj   +2 more sources

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis [PDF]

Critical Care, 2014
INTRODUCTION: A major pathophysiologic mechanism in sepsis is impaired host immunity which results in failure to eradicate invading pathogens and increased susceptibility to secondary infections.
Andriani C Patera, Bryan Sato, Catherine Svabek, Cristina Vazquez-Guillamet, David Rasche, JoAnn Suzich, Jonathan Green, Katherine Chang, Nancy Ulbrandt, Paul Robbins, Richard Hotchkiss, Strother Wilson, Subramaniam Krishnan, Wade Blair   +13 more
core   +6 more sources

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis [PDF]

Critical Care, 2018
Debasree Banerjee, Sean Monaghan, Runping Zhao, Thomas Walsh, Amy Palmisciano, Gary S. Phillips, Steven Opal, Mitchell M. Levy   +7 more
doaj   +3 more sources

Programmed Cell Death Ligand 1 Expression in Osteosarcoma [PDF]

Cancer Immunology Research, 2014
Abstract Programmed cell death ligand 1 (PDL1, also known as B7H1) is a cell-surface protein that suppresses the cytotoxic CD8+ T-cell–mediated immune response. PDL1 expression and its clinical relevance in sarcomas are not well understood.
Jacson K, Shen, Gregory M, Cote, Edwin, Choy, Pei, Yang, David, Harmon, Joseph, Schwab, G Petur, Nielsen, Ivan, Chebib, Soldano, Ferrone, Xinhui, Wang, Yangyang, Wang, Henry, Mankin, Francis J, Hornicek, Zhenfeng, Duan   +13 more
openaire   +2 more sources

Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study

Surgery Open Science, 2021
Background: Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy.
Nicholas J. Skertich, MD, Fei Chu, MD, PhD, Imad AM Tarhoni, MD, PhD, Stephen Szajek, MS, Jeffrey A. Borgia, PhD, Mary Beth Madonna, MD   +5 more
doaj   +1 more source

Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon

SAGE Open Medicine, 2021
Introduction: Programmed death ligand-1 expression has been shown to be a good predictor of response to cancer therapy with checkpoint inhibitors. Its expression varies among different tumor types and among non-small cell lung cancer patients with ...
Ghina Fakhri, Reem Akel, Ibrahim Khalifeh, Hassan Chami, Adel Hajj Ali, Majd Al Assaad, Haneen Atwi, Humam Kadara, Arafat Tfayli   +8 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Haematologica, 2016
Therapeutic strategies targeting the programmed cell death-ligand 1/programmed cell death-1 pathway have shown significant responses and good tolerability in solid malignancies.
Fabienne McClanahan, Thomas G. Sharp, John G. Gribben   +2 more
doaj   +1 more source